Peter Rankin and Andrew Tepperman published an article entitled “Biosimilars: economics and intellectual property,” which appeared in IPPro Life Sciences. The article discusses new challenges and opportunities innovators face relating to their IP rights with the onset of biosimilars. To read the article, click the link below.
The science of credibility: Communicating complex science to diverse stakeholders
Effective delivery depends on whether the audience perceives both the message and its source as credible. CRA recently hosted a forum to discuss the importance...